All In Biotech

Drug Trial Radar · NCT02561988

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Last checked: Nov 20, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Mar 10, 2016

Primary completion

Oct 5, 2022

Study completion Jan 19, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

Conditions

  • Aggressive Systemic Mastocytosis
  • Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
  • Mast Cell Leukemia
  • Relapsed or Refractory Myeloid Malignancies

Interventions

  • AvapritinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of avapritinib (also known as BLU-285)Time frame: During cycle 1 (28 days) of treatment
  2. Number of patients with adverse and serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findingsTime frame: Approximately 24 months
  3. Recommended Phase 2 dose (RP2D) of avapritinibTime frame: Approximately 24 months

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Stanford, California

  • University of Colorado Cancer Center

    Denver, Colorado

  • Emory University

    Atlanta, Georgia

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Mount Sinai Hospital

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Guy's Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.